Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

DCOY stock hub

Decoy Therapeutics Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

DCOYis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

DCOY

In the news

Latest news · DCOY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-661.7

P25 -105.6P50 -46.5P75 -3.1

ROIC-143.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All DCOY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001615219
Company name	Decoy Therapeutics Inc.
Country	United States
Country code	US
Cusip	79400X602
Employees	11
Employees Change	9%
Employees Change Percent	450
Enterprise value	$-4.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US79400X6022
Last refreshed	2026-05-10
Market cap	$3M
Market cap category	Nano-Cap
Price	$5.72
Price currency	USD
Sector	Healthcare
Symbol	DCOY
Website	https://decoytx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-428.33%
FCF yield	-214.76%
P/B ratio	0.78x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-13M
Net Income Growth Years	0%
Profit Per Employee	$-1.2M
ROA	-54.13
Roa5y	-52.59
ROCE	-120.2
ROE	-661.7
Roe5y	-166.6
ROIC	-143.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-95.56%
Cagr3y	-87.05%
Cagr5y	-83.32%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$8.4M
Cash	$7.8M
Current Assets	$8.4M
Current Liabilities	$4.5M
Equity	$3.9M
Liabilities	$4.5M
Long Term Assets	$65,623
Long Term Liabilities	$0
Net Cash	$7.8M
Net Cash By Market Cap	$257
Net Cash Growth	363.81%
Net Debt Equity	$-2.02
Tangible Book Value	$3.9M
Tangible Book Value Per Share	$7.29
WACC	6.33

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.84
Net Working Capital	$-4M
Quick ratio	1.72
Working Capital	$3.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-178.55%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-95.55%
200-day SMA	30.48
3Y total return	-99.78%
50-day SMA	6.63
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.99%
All Time High	533,354
All Time High Change	-100%
All Time High Date	2019-07-25
All Time Low	5.15
All Time Low Change	11.07%
All Time Low Date	2026-04-28
ATR	0.48
Beta	0.38
Beta1y	1.71
Beta2y	1.58
Ch YTD	-26.53
High	6.01
High52	415.8
High52 Date	2025-07-29
High52ch	-98.62%
Low	5.7
Low52	5.15
Low52 Date	2026-04-28
Low52ch	11.07%
Ma50ch	-13.78%
Price vs 200-day SMA	-81.23%
RSI	42.65
RSI Monthly	22.97
RSI Weekly	28.13
Sharpe ratio	-1.24x
Sortino ratio	-1.87
Total Return	-178.55%
Tr YTD	-26.53
Tr1m	-2.14%
Tr1w	-3.05%
Tr3m	-38.88%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-4.08
Operating Income	$-4.7M
Price target	$30
Price Target Change	$424

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	528,439%
Float Percent	99.34%
Net Borrowing	-112,230
Shares Insiders	0.66%
Shares Institutions	0.88%
Shares Out	531,968
Shares Qo Q	38.99%
Shares Yo Y	178.55%
Short Float	4.4%
Short Ratio	0.79
Short Shares	4.37

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-6.9M
Average Volume	10,559.3x
Bv Per Share	7.29
Ch1m	-2.14
Ch1w	-3.05
Ch1y	-95.55
Ch3m	-38.88
Ch3y	-99.78
Ch5y	-99.99
Ch6m	-80.46
Change	-0.35%
Change From Open	0.35
Close	5.74
Days Gap	-0.7
Depreciation Amortization	11,969
Dollar Volume	38,589.7
Earnings Date	2026-05-08
Earnings Time	amc
EBIT	$-4.7M
EBITDA	$-4.6M
EPS	$-57.12
F Score	2
FCF	$-6.5M
FCF EV Yield	136.78x
FCF Per Share	$-12.28
Financing CF	11,792,296
Fiscal Year End	December
Investing CF	764,735
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-08
Last Report Date	2026-03-31
Last Split Date	2026-03-09
Last Split Type	Reverse
Ma150	14.97
Ma150ch	-61.8%
Ma20	5.79
Ma20ch	-1.23%
Net CF	6,022,228
Next Earnings Date	2026-05-12
Open	5.7
Optionable	No
Position In Range	6.45
Post Close	5.72
Postmarket Change Percent	-0.35
Postmarket Price	$5.7
Ppne	35,741
Price Date	2026-05-08
Ptbv Ratio	0.78
Relative Volume	0.64x
Share Based Comp	398,568
Tr6m	-80.46%
Us State	Texas
Volume	6,746.4

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does DCOY pay a dividend?

Capital-return profile for this ticker.

Performance

DCOY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns DCOY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+0.9%

Float: +99.3% of shares outstanding

Insider ownership

+0.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

DCOY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

42.7

Neutral momentum band

Price vs 200-day MA

-81.2%

50/200-day relationship not available

Beta (5Y)

0.38

Less volatile than the market

Sharpe ratio

-1.24

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About DCOY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current DCOY stock rating?

Decoy Therapeutics Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DCOY analysis?

The full report lives at /stocks/DCOY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for DCOY?

The latest report frames DCOY around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the DCOY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.